If You Invested in Evotec Ag (EVO)

Evotec SE (NASDAQ: EVO; Frankfurt: EVT) is a life science company focused on drug discovery and development. According to the company’s disclosures, Evotec integrates breakthrough science with AI-driven innovation and advanced technologies to accelerate the path from concept to potential therapies with greater speed and precision.

Evotec’s expertise spans small molecules, biologics, cell therapies and associated modalities. These capabilities are supported by proprietary platforms such as Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. The company positions these platforms as the foundation for discovering and developing new therapeutic candidates across multiple disease areas.

Business model and partnerships

Evotec states that it works with all Top 20 pharmaceutical companies, more than 800 biotechnology firms, as well as academic institutions and other healthcare stakeholders. Its partnering models range from standalone discovery or development services to fully integrated R&D programs and long-term strategic collaborations. Many of its proprietary R&D assets are co-owned with partners, reflecting a shared-risk, shared-reward approach.

The company reports a portfolio of over 100 proprietary R&D assets, most of them co-owned. These assets and collaborations focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, immunology, and kidney diseases. Evotec also participates in multi-target research collaborations, for example with Bayer in kidney diseases and with Bristol Myers Squibb in protein degradation and neuroscience, as described in recent news.

Discovery & Preclinical Development and Just - Evotec Biologics

Evotec has described two major reporting segments in its financial communication. The segment formerly known as Shared R&D has been renamed Discovery & Preclinical Development (D&PD) to better reflect its strategic focus. This segment covers early drug discovery and preclinical development services and partnerships. The company has noted that this market can experience periods of soft demand, but it continues to highlight progress in core collaborations and its partnered asset pipeline.

The second major segment is Just - Evotec Biologics (JEB), which the company characterizes as a biologics platform business. JEB focuses on biologics development and manufacturing and is described as transitioning toward an asset-lighter model that emphasizes technology and intellectual property. Evotec reports that JEB has shown strong revenue growth, particularly with non-Sandoz and non-Department of Defense customers, and that it is central to the company’s strategy to become a scalable technology provider for next-generation biologics.

Technologies and platforms

Evotec highlights several proprietary technology platforms in its public communications:

• Molecular Patient Databases, which support data-driven target and biomarker discovery.
• PanOmics, combining high-end proteomics and transcriptomics at industrial scale for comprehensive cell biological profiling.
• PanHunter, a data analysis platform used to integrate and analyze PanOmics data to select promising drug candidates.
• iPSC-based disease modeling, enabling disease-relevant in vitro systems for discovery and safety assessment.

Through its subsidiary Just - Evotec Biologics, Evotec also emphasizes platforms for biologics, such as the J.DESIGN platform and its molecular design suite J.MD™, which integrate computational tools and high-throughput methods to optimize monoclonal antibodies and other biologic modalities. The company further refers to perfusion-based continuous manufacturing technologies and the J.POD concept for biologics manufacturing.

Strategic collaborations and transactions

Evotec’s strategy, as reflected in recent announcements, places significant weight on long-term strategic partnerships. Examples include:

• A multi-target collaboration with Bayer in kidney diseases, from which a monoclonal antibody program for Alport syndrome has advanced into Phase 2 clinical development.
• A strategic protein degradation partnership with Bristol Myers Squibb, focused on molecular glue degraders and CELMoD™ compounds, which has led to an accepted Investigational New Drug application for a cereblon E3 ligase modulator.
• A long-running neuroscience collaboration with Bristol Myers Squibb targeting neurodegenerative diseases, including programs such as EVT8683 (BMS-986419) that have progressed through early clinical stages.

Evotec has also reported a landmark transaction with Sandoz involving the sale of the Just - Evotec Biologics Toulouse site and an indefinite technology license to its continuous manufacturing platform. The company describes this transaction as a key step in transitioning JEB to an asset-lighter, technology-focused model while retaining capacity for molecular design, development, and biologics GMP manufacturing in other locations.

Therapeutic focus and global footprint

Across its proprietary and partnered pipeline, Evotec concentrates on oncology, cardiovascular and metabolic diseases, neurology, immunology, and kidney diseases. The company also participates in global health initiatives, such as grants from the Gates Foundation to support antibody design and tuberculosis treatment regimens, and collaborations targeting infectious diseases.

Evotec reports a global team of more than 4,800 experts operating from sites in Europe and the United States. These sites are described as complementary centers of excellence that offer synergistic technologies and services across the drug discovery and development value chain.

Evotec SE as a stock

Evotec SE’s shares trade on the Frankfurt Stock Exchange (Prime Standard, SDAX/TecDAX) under the symbol EVT and on NASDAQ under the symbol EVO. The company files reports as a foreign private issuer under Form 20-F and submits interim information on Form 6-K. Recent SEC filings have covered financial results, strategic transactions, and adjustments to guidance, as well as the initiation of a share repurchase program.

Investors reviewing Evotec as a stock can use these disclosures to understand its focus on platform-based drug discovery, its emphasis on co-owned assets and long-term collaborations, and its ongoing shift toward technology licensing and asset-lighter models in biologics manufacturing.